Leadership

Driven by experience. Guided by purpose.

Kihealth Europe is guided by an experienced team of healthcare executives, physicians, scientists, and industry leaders committed to advancing precision diagnostics, translational research, and earlier disease detection.

Executive Leadership

The people driving innovation forward.

An operating team uniting healthcare, diagnostics, policy, and commercialization experience across global markets.

Chief Executive Officer & Co-Founder

Jenna Anderson

Jenna Anderson is the Co-Founder and Chief Executive Officer of Kihealth, where she leads strategy, commercialization, fundraising, and growth initiatives. With more than two decades of experience spanning healthcare, biotechnology, digital health, and consumer wellness, Jenna has built and scaled innovative organizations at the intersection of science and technology. Prior to Kihealth, she held executive leadership roles at AccessElite, Concierge Key Health, ALPHAEON Corporation, and Allergan, leading sales, marketing, product development, and commercialization. She is passionate about transforming healthcare through earlier detection, prevention, and precision diagnostics.

Strategic VisionGrowth LeadershipInvestor Relations

Connect

Co-Founder & Chief Operating Officer

Robert E. Mons III

Robert E. Mons III is the Co-Founder and Chief Operating Officer of Kihealth, overseeing operations, business development, strategic partnerships, government affairs, and corporate growth. Prior to co-founding Kihealth, Robert spent six years serving in the United States Congress and later held senior leadership positions within Florida state government, building deep expertise in healthcare policy, public affairs, and regulatory strategy. He has held executive roles at Islet Sciences and Meraki Capital, and is the founder of Monstrong Fitness. His work positions Kihealth at the forefront of disease interception and precision medicine in Europe and beyond.

OperationsStrategic PartnershipsRegulatory Compliance

Connect

Scientific Leadership

Scientific, clinical, and laboratory expertise.

The scientific, medical, and laboratory leaders translating Kihealth's molecular diagnostics platform into rigorous clinical practice.

Chief Scientific Officer

Dr. Clifford Morris, PhD

Dr. Clifford Morris is a molecular biologist and diagnostics innovator with extensive experience in biomarker discovery, translational research, assay development, and precision medicine. As Chief Scientific Officer, he leads Kihealth's scientific strategy, research collaborations, platform expansion, and product development. His work spans molecular diagnostics, biomarker validation, clinical research, and the translation of scientific discoveries into commercial healthcare solutions — guiding the InterceptIQ™ platform and the BetaIntercept™ programs.

R&D LeadershipBiomarker DiscoveryTranslational Science

Connect

Chief Medical Officer

Dr. Matthew R. Benson, MD

Dr. Matthew Benson is a board-certified pediatric endocrinologist and nationally recognized diabetes specialist serving as Medical Director of the Northeast Florida Pediatric Diabetes Center at Nemours Children's Health. He has led numerous clinical trials and translational research programs focused on Type 1 diabetes, obesity, and metabolic disease. As Chief Medical Officer, Dr. Benson provides clinical leadership across research, regulatory strategy, physician engagement, clinical validation, and precision medicine initiatives for Kihealth Europe.

Clinical StrategyMedical OversightPrecision Medicine

Connect

Laboratory Director

Dr. Ioan Cucoranu, MD, FCAP

Dr. Ioan Cucoranu is an accomplished laboratory physician, molecular diagnostician, and laboratory operations leader. As Laboratory Director, he oversees clinical laboratory operations, CLIA-certified workflows, quality systems, assay implementation, and regulatory compliance. With deep expertise in molecular pathology, advanced diagnostic testing, clinical validation, and high-complexity laboratory management, Dr. Cucoranu ensures Kihealth maintains the highest standards of scientific rigor and analytical performance across its European operations.

CLIA LeadershipMolecular DiagnosticsQuality Systems

Connect

Board of Directors

Independent oversight. Operator pedigree.

Kihealth's board pairs deep capital-markets discipline with operators who have scaled category-defining companies — guiding strategy, governance, and long-horizon value creation.

Chairman of the Board

Scott A. Blum

Visionary entrepreneur and Founder of ThinkTank Holdings LLC, a private investment firm focused on technology, commerce, and media. Scott founded Buy.com — one of the earliest and most successful e-commerce platforms — and has scaled ventures including Luxury Card and Dutch Design. His expertise in scaling companies, optimizing operations, and driving disruption positions Kihealth at the intersection of healthcare and technology.

ScalingCapital StrategyDisruption

Connect

Director

Parker Kelley, CPA

Seasoned financial strategist and California CPA with a career spanning corporate finance, public accounting, and investment management. Parker has been instrumental at Kramer-Wilson Company (consolidated assets ~$618M as of Dec 2023). As founding CFO of KW Specialty Insurance, he built the company to a $101M statutory surplus and an A.M. Best A- (Excellent) rating. Previously at Warner Music Group and Holthouse Carlin & Van Trigt.

Fiscal StrategyOperationsInvestment Structuring

Connect

Director

Cameron Gray, PhD, JD

Distinguished biotechnology and investment leader. Founder and CEO of Alcedo Capital; previously Managing Director at MDB Capital Group funding disruptive technology companies, and Senior Investment Banker at Paulson Investment Company. Former CEO and board member of Endeavor IP, Inc. and SVP at ICAP Patent Brokerage. PhD in Biophysics (University of Virginia), JD (George Washington University Law School), BA in Physics (Princeton).

BiotechCapital MarketsIP Strategy

Connect

Scientific Advisory Board

A standing council of field-defining scientists.

The SAB guides program data review, biomarker discovery, and clinical study design — bringing world-class expertise across diabetes, endocrinology, immunology, and precision medicine.

Scientific Advisor — Diabetes Research & Regenerative Medicine

Dr. Camillo Ricordi

Internationally renowned physician-scientist and Director Emeritus of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine. A pioneer in islet transplantation, diabetes prevention, cell therapy, and translational medicine, Dr. Ricordi has authored hundreds of peer-reviewed publications and is recognized as a leading international voice in regenerative medicine.

Cell TransplantationRegenerative MedicineTranslational Science

Connect

Scientific Advisor — Immunology & Disease Interception

Dr. Kevan Herold

Professor of Immunobiology and Medicine at Yale School of Medicine and one of the world's leading experts in Type 1 diabetes prevention and immunotherapy. His research contributed to the development of teplizumab, the first FDA-approved therapy shown to delay the onset of Type 1 diabetes. Dr. Herold has spent decades advancing autoimmune disease research, beta-cell preservation, and disease interception.

Type 1 DiabetesImmunologyTherapeutic Development

Connect

Clinical Advisor — Pediatric Endocrinology

Dr. Larry Fox

Chief of Pediatric Endocrinology at Nemours Children's Health and a nationally recognized clinician with more than 34 years of experience in pediatric endocrinology and diabetes care. Dr. Fox has led clinical research, physician education, and multidisciplinary diabetes programs, providing Kihealth Europe with expertise in clinical trial leadership and the integration of novel diagnostic technologies into routine care.

Type 1 DiabetesClinical ResearchDiabetes Advocacy

Connect

Clinical Advisor — Precision Medicine

Dr. Shadi Abdelnour

Board-certified endocrinologist at Cedars-Sinai Medical Center with more than 20 years of clinical experience in diabetes, obesity, insulin resistance, dyslipidemia, and metabolic disease. Dr. Abdelnour combines evidence-based care with advances in precision medicine, contributing expertise in biomarker development, clinical diagnostics, healthcare innovation, and translational science.

Precision MedicineBiomarker DevelopmentClinical Diagnostics

Connect